Full Press Release Details
immatics' Renal Cancer Vaccine IMA901 Completes Phase 3 Patient Recruitment and is Granted US Orphan Drug Designation by the FDA.
IMTX
immatics' Renal Cancer Vaccine IMA901 Completes Phase 3 Patient Recruitment and is Granted US Orphan Drug Designation by the FDA
Key Takeaway: immatics' Renal Cancer Vaccine IMA901 Completes Phase 3 Patient Recruitment and is Granted US Orphan Drug Designation by the FDA